IBA SA : IBA Signs Contract to Install Proton Therapy Center in China

29 juni 2016

IBA Signs Contract to Install Proton Therapy Center in China
              

Louvain-La-Neuve, Belgium, June 29, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract with Qingdao Zhong Jia Lian He Healthcare Management Company Limited to install a Proteus ^® PLUS* multi-room solution in Qingdao, Shandong Province, China. The contract is worth more than EUR 80 million to IBA, including a long term service contract.

IBA will equip the new center with five treatment rooms, four isocentric-gantry treatment rooms and a fixed-beam treatment room, including the latest generation of precision technologies in Adaptive Intensity Modulated Proton Therapy: Pencil Beam Scanning and Cone Beam CT. The contract includes an operations and maintenance agreement and will also provide all dosimetry equipment to ensure the safest and fastest commissioning of the center. Qingdao Zhong Jia Lian He Healthcare Management Company Limited expects to be treating patients at the center by the end of 2018.

Olivier Legrain, Chief Executive Officer of IBA, commented: "This new collaboration with Qingdao Zhong Jia Lian He Healthcare Management Company Limited further strengthens IBA's world leading position in proton therapy. The Proteus ^® PLUS proton therapy center in China will be one of the largest in the world, as well as being one of the most technically advanced, with the highest quality therapeutic and imaging capabilities. IBA is pleased to be playing an important role in bringing such innovative cancer treatment modalities to patients in China."

Wang Xiang Yu, of Qingdao Zhong Jia Lian He Healthcare Management Company Limited said: "We want to have the most innovative treatments for our cancer patients in order to effectively fight this severe disease; proton therapy will help give our team of oncologists the critical tools to fight cancer. Our new Proteus ^® PLUS multi-room solution, including Pencil Beam Scanning and Cone Beam CT technology, will be installed by IBA and will allow us to 'paint' tumors with a super-fine beam of protons, destroying cancer cells whilst leaving surrounding healthy tissue untouched."

***ENDS***

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.  In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

* Proteus ^® PLUS is the brand name of a new configuration of the Proteus ^® 235

About Qingdao Zhong Jia Lian He Healthcare Management Company Limited
Qingdao Zhong Jia Lian He Healthcare Management Company Limited is a fully owned subsidiary of Hong Kong Zhong Jia Healthcare Group. The company is responsible for building oncology Hospitals and Class AAA General Hospitals throughout China; and will equip each of them with Proton Therapy facilities. This Qingdao Hospital investment including a Proton Therapy facility is worth 2 billion Chinese Yuan.

For further information please contact:   IBA Jean-Marc Bothy Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com   Thomas Ralet Vice-President Corporate Communication +32 10 475 890 Communication@iba-group.com

For media and investor enquiries:   Consilium Strategic Communications Amber Fennell, Matthew Neal, Ivar Milligan +44 (0) 20 3709 5700 IBA@consilium-comms.com   Rx Communications Group (US) Melody Carey + 1 917 322 2571 mcarey@RxIR.com

---